

# **Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/NF47F2EDA20BEN.html>

Date: November 2022

Pages: 125

Price: US\$ 3,500.00 (Single User License)

ID: NF47F2EDA20BEN

## **Abstracts**

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

According to the recently published report 'Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update'; Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 37 molecules.

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an important role in inflammation.

The report outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2

(TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 6, 9, 2, 12 and 6 respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Dermatology, Musculoskeletal Disorders, Oncology, Central Nervous System, Infectious Disease, Respiratory, Metabolic Disorders, Ophthalmology and Undisclosed which include indications Autoimmune Disorders, Psoriasis, Systemic Lupus Erythematosus, Plaque Psoriasis (Psoriasis Vulgaris), Inflammatory Bowel Disease, Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Psoriatic Arthritis, Ulcerative Colitis, Inflammation, Unspecified Immunological Disorders, Asthma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19), Crohn's Disease (Regional Enteritis), Dermatomyositis, Multiple Sclerosis, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Alopecia Areata, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Chronic Obstructive Pulmonary Disease (COPD), Chronic Urticaria Or Hives, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Enteritis, Fibrosis, Follicular Lymphoma, Hidradenitis Suppurativa, Intermediate Uveitis, Kidney Cancer (Renal Cell Cancer), Lupus Erythematosus, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Neuroinflammation, Non-infectious Uveitis, Pancreatic Cancer, Panuveitis, Peripheral T-Cell Lymphomas (PTCL), Posterior Uveitis, Skin Cancer, Solid Tumor, Subacute Cutaneous Lupus Erythematosus (SCLE), Unspecified, Unspecified B-Cell Lymphomas, Unspecified Dermatological Disorders, Vitiligo and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and

industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Overview

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics  
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics  
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies  
Involved in Therapeutics Development

A2A Pharmaceuticals Inc

Alexion Pharmaceuticals Inc

Alumis Inc

Amgen Inc

Atomwise Inc

BeiGene Ltd

Bristol-Myers Squibb Co

Galapagos NV

Haisco Pharmaceutical Group Co Ltd

InnoCare Pharma Ltd

Kinaset Therapeutics Inc

Merck & Co Inc

Neuron23 Inc

Nimbus Therapeutics LLC

Oncostellae SL

Pfizer Inc

Priovant Therapeutics Inc

Sareum Holdings Plc

Shenzhen Chipscreen Biosciences Co Ltd

Sincere Pharmaceutical Group Ltd

Sudo Biosciences Inc

Technoderma Medicines Inc

Theravance Biopharma Inc

TLL Pharmaceutical LLC

Ventyx Biosciences Inc

Xilingyuan Pharmaceutical Co Ltd

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles

A2A-I-01 - Drug Profile

Product Description

Mechanism Of Action

BGB-23339 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BMS-986322 - Drug Profile

Product Description

Mechanism Of Action

History of Events

brepocitinib tosylate - Drug Profile

Product Description

Mechanism Of Action

History of Events

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

History of Events

CS-43001 - Drug Profile

Product Description

Mechanism Of Action

deucravacitinib - Drug Profile

Product Description

Mechanism Of Action

History of Events

ESK-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

FTP-637 - Drug Profile

Product Description

Mechanism Of Action

History of Events  
GLPG-3667 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
ICP-332 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
ICP-488 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
KN-002 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
NDI-031407 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
NDI-034858 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Oral TYK2 (JH2) - Drug Profile  
Product Description  
Mechanism Of Action  
OST-122 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
QY-201 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
SAR-20347 - Drug Profile  
Product Description  
Mechanism Of Action

History of Events

SDC-1801 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SDC-1802 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1 and TYK2 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit TYK2 for Inflammatory Disorders and Neuroinflammation - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit TYK2 for Unspecified Immunological Disorders - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit JAK1, JAK2, JAK3 and TYK2 for Dermatology - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit TYK2 for Inflammation - Drug Profile



Product Description  
Mechanism Of Action  
History of Events  
SMP-117 - Drug Profile  
Product Description  
Mechanism Of Action  
TDM-180935 - Drug Profile  
Product Description  
Mechanism Of Action  
TDMSLE-01 - Drug Profile  
Product Description  
Mechanism Of Action  
TLL-018 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
TYK2 (JH2) Program 2 - Drug Profile  
Product Description  
Mechanism Of Action  
TYK2 (JH2) Program 3 - Drug Profile  
Product Description  
Mechanism Of Action  
TYK2 (JH2) Program 4 - Drug Profile  
Product Description  
Mechanism Of Action  
VTX-958 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Products  
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued Products  
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Product Development Milestones  
Featured News & Press Releases  
Nov 08, 2022: Sareum Holdings : Update on SDC-1801 CTA application  
Sep 28, 2022: Alumis announces initiation of patient dosing in phase 2 clinical trial of ESK-001 for the treatment of plaque psoriasis  
Sep 12, 2022: Bristol Myers Squibb announces new Sotyktu (deucravacitinib) long-term

data showing clinical efficacy maintained for up to two years with continuous treatment in moderate-to-severe plaque psoriasis

Sep 09, 2022: US FDA grants approval for BMS' Sotyktu to treat plaque psoriasis

Aug 24, 2022: Nimbus Therapeutics presents new data on oral allosteric TYK2 inhibitor at American Chemical Society Meeting

Aug 15, 2022: Ventyx Biosciences announces positive topline phase 1 data for its selective allosteric TYK2 inhibitor VTX95

Aug 11, 2022: Ventyx Biosciences to report topline results from the phase 1 trial of its TYK 2 inhibitor VTX958 and second quarter 2022 financial results on August 15, 2022

Aug 02, 2022: InnoCare announces first subject dosed in clinical trial of TYK2 JH2 allosteric inhibitor ICP-488 in China

Jul 28, 2022: Sareum submits clinical trial authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an operational update

Jun 28, 2022: Roivant and Pfizer unveil Priovant Therapeutics and ongoing registrational studies for oral Brepocitinib in dermatomyositis and lupus

Jun 01, 2022: Late-Breaking data at EULAR 2022 demonstrate deucravacitinib significantly improved disease activity in phase 2 PAISLEY study in Systemic Lupus Erythematosus

Jun 01, 2022: Lupus Research Alliance and Lupus Therapeutics response to positive data from phase 2 study on potential first-in-class lupus treatment

May 19, 2022: Nimbus Therapeutics presents additional clinical data from phase 1 studies of oral allosteric TYK2 inhibitor at SID Annual Meeting

May 12, 2022: New two-year deucravacitinib data reinforce durable efficacy and consistent safety profile in treatment of moderate to severe plaque psoriasis

Apr 11, 2022: European patent granted for Sareum's SDC-1802, a novel small molecule TYK2/JAK1 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by A2A Pharmaceuticals Inc, 2022

Pipeline by Alexion Pharmaceuticals Inc, 2022

Pipeline by Alumis Inc, 2022

Pipeline by Amgen Inc, 2022

Pipeline by Atomwise Inc, 2022

Pipeline by BeiGene Ltd, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Galapagos NV, 2022

Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022

Pipeline by InnoCare Pharma Ltd, 2022

Pipeline by Kinaset Therapeutics Inc, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by Neuron23 Inc, 2022

Pipeline by Nimbus Therapeutics LLC, 2022

Pipeline by Oncostellae SL, 2022

Pipeline by Pfizer Inc, 2022

Pipeline by Priovant Therapeutics Inc, 2022

Pipeline by Sareum Holdings Plc, 2022

Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022

Pipeline by Simcere Pharmaceutical Group Ltd, 2022

Pipeline by Sudo Biosciences Inc, 2022

Pipeline by Technoderma Medicines Inc, 2022

Pipeline by Theravance Biopharma Inc, 2022

Pipeline by TLL Pharmaceutical LLC, 2022

Pipeline by Ventyx Biosciences Inc, 2022  
Pipeline by Xilingyuan Pharmaceutical Co Ltd, 2022  
Dormant Products, 2022  
Dormant Products, 2022 (Contd..1)  
Dormant Products, 2022 (Contd..2)  
Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

## I would like to order

Product name: Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/NF47F2EDA20BEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NF47F2EDA20BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970